This task order is for the proteomic characterization laboratory.
Active Awarded Last action
- Contract number
- 75N91021F00010
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $17,159,340
Award facts
- Opportunity
-
- NCIARCDCTD210107 Solicitation number
- Contract value 77% obligated
-
- $17,159,340.00 Current, with exercised options
- $22,388,857.00 Potential, with all options
- Completion date 73% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $2,072,543 | |
| Terminate for Convenience | -$300,825 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $6,876,079 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,120,234 | |
| Other Administrative Action | $0 | |
| Original award | $6,391,309 |
About this award
This delivery order task, awarded September 25, 2021, provides $22.4 million in funding to Leidos Biomedical Research Inc. for proteomic characterization laboratory services supporting the National Cancer Institute (NCI). The contract operates on a cost-plus-fixed-fee pricing model with performance through September 24, 2028, and will be executed at the company's Frederick, Maryland facility. The award carries no small business set-aside designation, reflecting Leidos Biomedical Research's competitive capabilities and established position as a Federally Funded Research and Development Center (FFRDC) contractor primarily serving the National Cancer Institute and National Institutes of Health.
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., specializes in comprehensive biomedical research and facilities support services with demonstrated expertise across multiple scientific domains including cancer research, gene therapy development, infectious disease investigation, and advanced laboratory analysis. The parent company, Leidos Holdings, maintains an extensive federal contracting portfolio valued in the billions of dollars across defense, intelligence, health, and critical infrastructure sectors. This proteomic characterization task order supports the NCI's research mission and builds upon the subsidiary's track record of delivering complex, multi-year scientific research initiatives and collaborative projects with leading academic institutions.
Quick answers
Who was awarded contract 75N91021F00010?
75N91021F00010 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2021.
How much is contract 75N91021F00010 worth?
The government has obligated $17,159,340 on 75N91021F00010. Its potential value, with all options, is $22,388,857.
Is contract 75N91021F00010 an order under another contract?
Yes. 75N91021F00010 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91021F00010 competed?
The extent of competition for 75N91021F00010 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award